I'll research BDX before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent Q2 2026 earnings call and release, plus recent news for the separation story.Let me get recent news context and the stock price trajectory heading into the print.The stock rallied notably in late July. Let me investigate what's driving that and check for the activist/strategic-review angle.Let me search the web for recent BDX developments driving the late-July move and the ChloraPrep resolution.Let me read the recent earnings preview and check for what drove the late-July rally.# BD (Becton Dickinson, NYSE: BDX) — Fiscal Q3 2026 Earnings Preview Report date: Thursday, August 6, 2026 (before U.S. open) | Period: Fiscal Q3 2026 (quarter ended June 30, 2026) | Call: 8:00 a.m. ET

---

The one-line setup

This is the first full quarter that reflects "New BD" as a pure-play medtech company — the Biosciences & Diagnostic Solutions (Life Sciences) unit was spun off and merged into Waters on February 9, 2026, and all comparisons are now on a continuing-operations basis. With the portfolio finally "clean," the debate has shifted from what BD is to whether BD can execute: can management convert an improving cost/cash story and a handful of double-digit growth platforms into durable mid-single-digit top-line growth, while the market re-rates a stock that management itself calls "substantially undervalued."

Where the stock sits going in

• BDX closed ~$170.69 on Aug 5, having rallied roughly +11–12% over the prior two weeks (from the low-$150s), including a ~4.7% jump on July 28. Momentum is firmly positive heading into the print, which raises the bar for a beat-and-raise reaction.
• The year has been a round trip: a spike to the mid-$180s right after the Waters spin closed in February, a slide to a ~$142 low in May (soft guidance optics + the ChloraPrep FDA warning letter), and a recovery back toward $170.
• Sentiment is neutral-to-constructive. Bulls point to portfolio simplification and a turnaround that could drive multiple expansion off depressed levels; bears cite BD's history of uneven execution and structurally muted top-line growth.

Consensus & what's implied

• Street is looking for ~$3.14 adjusted EPS (down ~14.7% vs. the recast year-ago $3.68 — the decline is optical, driven by the loss of Life Sciences earnings post-spin) and ~2.6% FX-neutral revenue growth.
• The math matters more than the Q3 point estimate. First-half adjusted EPS was $5.38, and full-year guidance is $12.52–$12.72 (raised at Q2). That implies ~$7.14–$7.34 in H2, so a ~$3.14 Q3 leaves an implied ~$4.00–$4.20 Q4 — a very back-half-weighted year. Q3 is therefore best read as a checkpoint on the H2 margin ramp, with the Q4 setup and any guidance refinement carrying the real signal.

What actually matters this quarter

1) Revenue quality: growth platforms vs. the "known 10%"

Management's framing: >90% of the portfolio is growing ~5% (mid-single digits), offset by a <10% bucket of deliberate headwinds — Alaris, vaccines, and China. Watch whether the growth platforms keep compounding: - BioPharma Systems / biologic drug delivery (GLP-1s): biologics are now ~55% of the segment (up from ~50%); two new next-gen GLP-1 programs and 80+ biosimilar deals signed. Note BD/EMS launched a semaglutide GLP-1 therapy in Brazil in late July. - Advanced Patient Monitoring (APM): grew ~12% in Q2 (HemoSphere Alta, Smart Recovery consumables); sales-force build-out now largely complete, so H2 is the "show me" period. - PureWick (Urology/UCC) and Advanced Tissue Regeneration — both double-digit; watch the PureWick at-home / VA expansion. - Alaris: ~50 bps of share gain in Q2 (~150 bps YTD), "largest competitive funnel in company history," but the capital comp is a ~100 bps FY26 headwind (stepping up to ~200 bps in FY27 before normalizing in FY28).

2) Margins, tariffs, and the H2 ramp

Q2 adjusted gross margin was 54.7% (−90 bps YoY) and adjusted operating margin 24.2% (−110 bps), both hit by ~160 bps of tariffs but better than expected. The full-year guide of ~25% adjusted operating margin requires a meaningful H2 step-up, driven by BD Excellence (~8% productivity, a $200M cost-out program already at a $150M run-rate). Key questions: is productivity still tracking, and how are tariffs / oil / resin (resins are ~5% of COGS, ~50% of N.A. resin hedged) trending — especially the FY27 cost setup, where hedges roll off and pricing actions become the lever.

3) ChloraPrep / PurPrep — largely behind them, but verify

BD received an FDA warning letter on the El Paso, TX facility and voluntarily placed ChloraPrep/PurPrep on U.S. ship hold; shipments resumed May 29, 2026 after additional final-release testing. Since the hold spanned part of fiscal Q3, watch for any residual revenue impact (mostly Surgery, some MDS), remediation-cost commentary, and confirmation there are no lingering regulatory overhangs. Separately, note a minor late-July recall of certain intraosseous vascular access needle sets.

4) Capital allocation — buyback-first

BD is leaning into repurchases at what it views as an undervalued price: $2.0B accelerated buyback and $2.1B of debt retired in Q2, net leverage ~2.9x (target 2.5x). The Board declared a $1.05/share quarterly dividend on July 28. M&A is now explicitly the #2 priority behind buybacks ("focused tuck-ins"). Watch free cash flow (H1 FCF ~$1.1B, up sharply) and pace of repurchases.

5) Leadership turnover — a lot of it

A notable cluster of management changes: Vitor Roque made permanent CFO; Rick Byrd (Interventional) retiring; Michael Garrison retiring with BioPharma Systems now reporting directly to the CEO; Mike Feld installed as Chief Revenue Officer. Investors should probe stability/continuity of the "compete, innovate, deliver" execution agenda given the churn.

Bull vs. bear into the print

Bull case: Clean pure-play story, growth platforms compounding double digits, best-in-class productivity engine, aggressive buyback at a low multiple, ChloraPrep resolved → beat-and-raise (again) drives re-rating. BD has topped EPS estimates each of the last several quarters.

Bear case: Underlying FX-neutral growth is still only ~2.6%; the year is heavily back-half loaded (large implied Q4); Alaris headwind worsens to 200 bps in FY27; tariff/resin costs and vaccine/China uncertainty cap margin upside; and the stock has already rallied ~12% into the number, so expectations are elevated.

Watch-list / scorecard for Aug 6

1. FX-neutral organic growth vs. ~2.6% — and the health of the ">90% growing ~5%" narrative.
2. Adjusted gross & operating margin trajectory and confirmation of the H2 ramp toward ~25%.
3. Full-year EPS guide — hold, raise, or narrow ($12.52–$12.72), and any tightening of the revenue outlook.
4. First read on FY27 — Alaris 200 bps headwind, tariff/resin inflation, and offsetting pricing/productivity.
5. Segment detail: BioPharma/GLP-1 momentum, APM post-hiring, Alaris consumables pull-through, China VBP.
6. Capital return cadence and net-leverage progress toward 2.5x.
7. Any residual ChloraPrep revenue/cost impact and quality/regulatory commentary.

Bottom line: With the portfolio simplification done and the stock already re-rating, the market has effectively priced in "execution is improving." The bar is now a clean FX-neutral growth print, visible margin acceleration into Q4, and — most importantly — enough confidence in the FY26 finish and early FY27 framing to justify the recent rally. Anything that reopens the "uneven execution" or "muted growth" narrative is the primary downside risk.

Note: figures reflect BD's continuing-operations basis post the Waters spin. Consensus estimates are as reported by third-party sources and may differ from your own model.